ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Guardant Health (GH)
Guardant Health stock price today, ATLAS forecast and fair value
Healthcare · Diagnostics & Research · NASDAQ
$178.06▲ +2.78%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
48%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Guardant Health in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Guardant Health
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Guardant Health a 48% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $162.05 and $193.59; in 9 out of 10, between $138.42 and $226.65. Estimated annual volatility is 46%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $23.9B
- 52-week high
- $191.05
- 52-week low
- $68.02
- Revenue (12 months)
- $1.2B
- Revenue growth (YoY)
- +32.9%
- Gross margin
- 64.5%
- Operating margin
- -44.5%
- Net margin
- -42.4%
- Return on equity
- 419.2%
- Free cash flow (12 months)
- $26.6M
- Beta
- 1.58
What this means
ATLAS does not publish a fair value for GH right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks GH has traded between $68.02 and $191.05. Today it is 6.8% below that high and 162% above its low.
On the business: revenue grew 32.9% year over year; net margin is 42.4%.
Its beta is 1.58: it tends to move more than the market, both up and down.
About the company
Guardant Health Inc. is a precision oncology company that develops blood- and tissue-based tests, data sets, and analytics to support cancer detection and treatment decisions.
Want to see everything about Guardant Health?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Guardant Health do?
Guardant Health Inc. is a precision oncology company that develops blood- and tissue-based tests, data sets, and analytics to support cancer detection and treatment decisions.
What is the chance GH goes up next month?
48%: close to a coin flip. In half of the simulated outcomes, GH ends the month between $162.05 and $193.59.
How big is Guardant Health and what is its P/E ratio?
Guardant Health's market capitalization is $23.9B. We do not show a P/E because it has no positive earnings to base one on.
How volatile is GH?
ATLAS estimates annual volatility at 46%. In a typical month, half of the outcomes end between $162.05 and $193.59.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer